IBDEI03Q ; ; 01-AUG-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,8942,1,4,0)
;;=4^D63.0
;;^UTILITY(U,$J,358.3,8942,2)
;;=^321978
;;^UTILITY(U,$J,358.3,8943,0)
;;=D63.8^^45^431^22
;;^UTILITY(U,$J,358.3,8943,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8943,1,3,0)
;;=3^Anemia in Chronic Diseases Classified Elsewhere
;;^UTILITY(U,$J,358.3,8943,1,4,0)
;;=4^D63.8
;;^UTILITY(U,$J,358.3,8943,2)
;;=^5002343
;;^UTILITY(U,$J,358.3,8944,0)
;;=C22.3^^45^431^27
;;^UTILITY(U,$J,358.3,8944,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8944,1,3,0)
;;=3^Angiosarcoma of Liver
;;^UTILITY(U,$J,358.3,8944,1,4,0)
;;=4^C22.3
;;^UTILITY(U,$J,358.3,8944,2)
;;=^5000936
;;^UTILITY(U,$J,358.3,8945,0)
;;=D61.9^^45^431^28
;;^UTILITY(U,$J,358.3,8945,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8945,1,3,0)
;;=3^Aplastic Anemia,Unspec
;;^UTILITY(U,$J,358.3,8945,1,4,0)
;;=4^D61.9
;;^UTILITY(U,$J,358.3,8945,2)
;;=^5002342
;;^UTILITY(U,$J,358.3,8946,0)
;;=D56.1^^45^431^34
;;^UTILITY(U,$J,358.3,8946,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8946,1,3,0)
;;=3^Beta Thalassemia
;;^UTILITY(U,$J,358.3,8946,1,4,0)
;;=4^D56.1
;;^UTILITY(U,$J,358.3,8946,2)
;;=^340495
;;^UTILITY(U,$J,358.3,8947,0)
;;=C83.79^^45^431^36
;;^UTILITY(U,$J,358.3,8947,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8947,1,3,0)
;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,8947,1,4,0)
;;=4^C83.79
;;^UTILITY(U,$J,358.3,8947,2)
;;=^5001600
;;^UTILITY(U,$J,358.3,8948,0)
;;=C83.70^^45^431^37
;;^UTILITY(U,$J,358.3,8948,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8948,1,3,0)
;;=3^Burkitt Lymphoma,Unspec Site
;;^UTILITY(U,$J,358.3,8948,1,4,0)
;;=4^C83.70
;;^UTILITY(U,$J,358.3,8948,2)
;;=^5001591
;;^UTILITY(U,$J,358.3,8949,0)
;;=D09.0^^45^431^44
;;^UTILITY(U,$J,358.3,8949,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8949,1,3,0)
;;=3^Carcinoma in Situ of Bladder
;;^UTILITY(U,$J,358.3,8949,1,4,0)
;;=4^D09.0
;;^UTILITY(U,$J,358.3,8949,2)
;;=^267742
;;^UTILITY(U,$J,358.3,8950,0)
;;=D06.9^^45^431^45
;;^UTILITY(U,$J,358.3,8950,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8950,1,3,0)
;;=3^Carcinoma in Situ of Cervix
;;^UTILITY(U,$J,358.3,8950,1,4,0)
;;=4^D06.9
;;^UTILITY(U,$J,358.3,8950,2)
;;=^5001941
;;^UTILITY(U,$J,358.3,8951,0)
;;=D06.0^^45^431^47
;;^UTILITY(U,$J,358.3,8951,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8951,1,3,0)
;;=3^Carcinoma in Situ of Endocervix
;;^UTILITY(U,$J,358.3,8951,1,4,0)
;;=4^D06.0
;;^UTILITY(U,$J,358.3,8951,2)
;;=^5001938
;;^UTILITY(U,$J,358.3,8952,0)
;;=D06.1^^45^431^48
;;^UTILITY(U,$J,358.3,8952,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8952,1,3,0)
;;=3^Carcinoma in Situ of Exocervix
;;^UTILITY(U,$J,358.3,8952,1,4,0)
;;=4^D06.1
;;^UTILITY(U,$J,358.3,8952,2)
;;=^5001939
;;^UTILITY(U,$J,358.3,8953,0)
;;=D06.7^^45^431^46
;;^UTILITY(U,$J,358.3,8953,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8953,1,3,0)
;;=3^Carcinoma in Situ of Cervix,Other Parts
;;^UTILITY(U,$J,358.3,8953,1,4,0)
;;=4^D06.7
;;^UTILITY(U,$J,358.3,8953,2)
;;=^5001940
;;^UTILITY(U,$J,358.3,8954,0)
;;=D04.9^^45^431^49
;;^UTILITY(U,$J,358.3,8954,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8954,1,3,0)
;;=3^Carcinoma in Situ of Skin
;;^UTILITY(U,$J,358.3,8954,1,4,0)
;;=4^D04.9
;;^UTILITY(U,$J,358.3,8954,2)
;;=^5001925
;;^UTILITY(U,$J,358.3,8955,0)
;;=C91.11^^45^431^52
;;^UTILITY(U,$J,358.3,8955,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8955,1,3,0)
;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
;;^UTILITY(U,$J,358.3,8955,1,4,0)
;;=4^C91.11
;;^UTILITY(U,$J,358.3,8955,2)
;;=^5001766
;;^UTILITY(U,$J,358.3,8956,0)
;;=C91.10^^45^431^53
;;^UTILITY(U,$J,358.3,8956,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8956,1,3,0)
;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
;;^UTILITY(U,$J,358.3,8956,1,4,0)
;;=4^C91.10
;;^UTILITY(U,$J,358.3,8956,2)
;;=^5001765
;;^UTILITY(U,$J,358.3,8957,0)
;;=C92.11^^45^431^54
;;^UTILITY(U,$J,358.3,8957,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8957,1,3,0)
;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
;;^UTILITY(U,$J,358.3,8957,1,4,0)
;;=4^C92.11
;;^UTILITY(U,$J,358.3,8957,2)
;;=^5001793
;;^UTILITY(U,$J,358.3,8958,0)
;;=C92.10^^45^431^55
;;^UTILITY(U,$J,358.3,8958,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8958,1,3,0)
;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
;;^UTILITY(U,$J,358.3,8958,1,4,0)
;;=4^C92.10
;;^UTILITY(U,$J,358.3,8958,2)
;;=^5001792
;;^UTILITY(U,$J,358.3,8959,0)
;;=D47.1^^45^431^56
;;^UTILITY(U,$J,358.3,8959,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8959,1,3,0)
;;=3^Chronic Myeloproliferative Disease
;;^UTILITY(U,$J,358.3,8959,1,4,0)
;;=4^D47.1
;;^UTILITY(U,$J,358.3,8959,2)
;;=^5002256
;;^UTILITY(U,$J,358.3,8960,0)
;;=C82.69^^45^431^57
;;^UTILITY(U,$J,358.3,8960,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8960,1,3,0)
;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,8960,1,4,0)
;;=4^C82.69
;;^UTILITY(U,$J,358.3,8960,2)
;;=^5001530
;;^UTILITY(U,$J,358.3,8961,0)
;;=C82.60^^45^431^58
;;^UTILITY(U,$J,358.3,8961,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8961,1,3,0)
;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
;;^UTILITY(U,$J,358.3,8961,1,4,0)
;;=4^C82.60
;;^UTILITY(U,$J,358.3,8961,2)
;;=^5001521
;;^UTILITY(U,$J,358.3,8962,0)
;;=D56.2^^45^431^59
;;^UTILITY(U,$J,358.3,8962,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8962,1,3,0)
;;=3^Delta-Beta Thalassemia
;;^UTILITY(U,$J,358.3,8962,1,4,0)
;;=4^D56.2
;;^UTILITY(U,$J,358.3,8962,2)
;;=^340496
;;^UTILITY(U,$J,358.3,8963,0)
;;=D75.9^^45^431^60
;;^UTILITY(U,$J,358.3,8963,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8963,1,3,0)
;;=3^Disease of Blood/Blood-Forming Organs,Unspec
;;^UTILITY(U,$J,358.3,8963,1,4,0)
;;=4^D75.9
;;^UTILITY(U,$J,358.3,8963,2)
;;=^5002393
;;^UTILITY(U,$J,358.3,8964,0)
;;=D59.0^^45^431^63
;;^UTILITY(U,$J,358.3,8964,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8964,1,3,0)
;;=3^Drug-Induced Autoimmune Hemolytic Anemia
;;^UTILITY(U,$J,358.3,8964,1,4,0)
;;=4^D59.0
;;^UTILITY(U,$J,358.3,8964,2)
;;=^5002323
;;^UTILITY(U,$J,358.3,8965,0)
;;=D59.2^^45^431^64
;;^UTILITY(U,$J,358.3,8965,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8965,1,3,0)
;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
;;^UTILITY(U,$J,358.3,8965,1,4,0)
;;=4^D59.2
;;^UTILITY(U,$J,358.3,8965,2)
;;=^5002325
;;^UTILITY(U,$J,358.3,8966,0)
;;=R59.9^^45^431^67
;;^UTILITY(U,$J,358.3,8966,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8966,1,3,0)
;;=3^Enlarged Lymph Nodes,Unspec
;;^UTILITY(U,$J,358.3,8966,1,4,0)
;;=4^R59.9
;;^UTILITY(U,$J,358.3,8966,2)
;;=^5019531
;;^UTILITY(U,$J,358.3,8967,0)
;;=D47.3^^45^431^68
;;^UTILITY(U,$J,358.3,8967,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8967,1,3,0)
;;=3^Essential Thrombocythemia
;;^UTILITY(U,$J,358.3,8967,1,4,0)
;;=4^D47.3
;;^UTILITY(U,$J,358.3,8967,2)
;;=^5002258
;;^UTILITY(U,$J,358.3,8968,0)
;;=C82.09^^45^431^69
;;^UTILITY(U,$J,358.3,8968,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8968,1,3,0)
;;=3^Follicular Lymphoma Grade I,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,8968,1,4,0)
;;=4^C82.09
;;^UTILITY(U,$J,358.3,8968,2)
;;=^5001470
;;^UTILITY(U,$J,358.3,8969,0)
;;=C82.00^^45^431^70
;;^UTILITY(U,$J,358.3,8969,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8969,1,3,0)
;;=3^Follicular Lymphoma Grade I,Unspec Site
;;^UTILITY(U,$J,358.3,8969,1,4,0)
;;=4^C82.00
;;^UTILITY(U,$J,358.3,8969,2)
;;=^5001461
;;^UTILITY(U,$J,358.3,8970,0)
;;=C82.19^^45^431^71
;;^UTILITY(U,$J,358.3,8970,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8970,1,3,0)
;;=3^Follicular Lymphoma Grade II,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,8970,1,4,0)
;;=4^C82.19
;;^UTILITY(U,$J,358.3,8970,2)
;;=^5001480
;;^UTILITY(U,$J,358.3,8971,0)
;;=C82.10^^45^431^72
;;^UTILITY(U,$J,358.3,8971,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8971,1,3,0)
;;=3^Follicular Lymphoma Grade II,Unspec Site
;;^UTILITY(U,$J,358.3,8971,1,4,0)
;;=4^C82.10
;;^UTILITY(U,$J,358.3,8971,2)
;;=^5001471
;;^UTILITY(U,$J,358.3,8972,0)
;;=C82.29^^45^431^73
;;^UTILITY(U,$J,358.3,8972,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8972,1,3,0)
;;=3^Follicular Lymphoma Grade III,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,8972,1,4,0)
;;=4^C82.29
;;^UTILITY(U,$J,358.3,8972,2)
;;=^5001490
;;^UTILITY(U,$J,358.3,8973,0)
;;=C82.20^^45^431^74
;;^UTILITY(U,$J,358.3,8973,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8973,1,3,0)
;;=3^Follicular Lymphoma Grade III,Unspec Site
;;^UTILITY(U,$J,358.3,8973,1,4,0)
;;=4^C82.20
;;^UTILITY(U,$J,358.3,8973,2)
;;=^5001481
;;^UTILITY(U,$J,358.3,8974,0)
;;=C82.39^^45^431^75
;;^UTILITY(U,$J,358.3,8974,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8974,1,3,0)
;;=3^Follicular Lymphoma Grade IIIa,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,8974,1,4,0)
;;=4^C82.39
;;^UTILITY(U,$J,358.3,8974,2)
;;=^5001500
;;^UTILITY(U,$J,358.3,8975,0)
;;=C82.30^^45^431^76
;;^UTILITY(U,$J,358.3,8975,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8975,1,3,0)
;;=3^Follicular Lymphoma Grade IIIa,Unspec Site
;;^UTILITY(U,$J,358.3,8975,1,4,0)
;;=4^C82.30
;;^UTILITY(U,$J,358.3,8975,2)
;;=^5001491
;;^UTILITY(U,$J,358.3,8976,0)
;;=C82.49^^45^431^77
;;^UTILITY(U,$J,358.3,8976,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8976,1,3,0)
;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,8976,1,4,0)
;;=4^C82.49
;;^UTILITY(U,$J,358.3,8976,2)
;;=^5001510
;;^UTILITY(U,$J,358.3,8977,0)
;;=C82.40^^45^431^78
;;^UTILITY(U,$J,358.3,8977,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8977,1,3,0)
;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
;;^UTILITY(U,$J,358.3,8977,1,4,0)
;;=4^C82.40
;;^UTILITY(U,$J,358.3,8977,2)
;;=^5001501
;;^UTILITY(U,$J,358.3,8978,0)
;;=C82.99^^45^431^79
;;^UTILITY(U,$J,358.3,8978,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8978,1,3,0)
;;=3^Follicular Lymphoma Unspec,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,8978,1,4,0)
;;=4^C82.99
;;^UTILITY(U,$J,358.3,8978,2)
;;=^5001550
;;^UTILITY(U,$J,358.3,8979,0)
;;=C82.90^^45^431^80
;;^UTILITY(U,$J,358.3,8979,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8979,1,3,0)
;;=3^Follicular Lymphoma Unspec,Unspec Site
;;^UTILITY(U,$J,358.3,8979,1,4,0)
;;=4^C82.90
;;^UTILITY(U,$J,358.3,8979,2)
;;=^5001541
;;^UTILITY(U,$J,358.3,8980,0)
;;=R59.1^^45^431^65
;;^UTILITY(U,$J,358.3,8980,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8980,1,3,0)
;;=3^Enlarged Lymph Nodes,Generalized
;;^UTILITY(U,$J,358.3,8980,1,4,0)
;;=4^R59.1
;;^UTILITY(U,$J,358.3,8980,2)
;;=^5019530
;;^UTILITY(U,$J,358.3,8981,0)
;;=C91.40^^45^431^84
;;^UTILITY(U,$J,358.3,8981,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8981,1,3,0)
;;=3^Hairy Cell Leukemia,Not in Remission
;;^UTILITY(U,$J,358.3,8981,1,4,0)
;;=4^C91.40
;;^UTILITY(U,$J,358.3,8981,2)
;;=^5001771
;;^UTILITY(U,$J,358.3,8982,0)
;;=C91.42^^45^431^82
;;^UTILITY(U,$J,358.3,8982,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8982,1,3,0)
;;=3^Hairy Cell Leukemia,In Relapse
;;^UTILITY(U,$J,358.3,8982,1,4,0)
;;=4^C91.42
;;^UTILITY(U,$J,358.3,8982,2)
;;=^5001773
;;^UTILITY(U,$J,358.3,8983,0)
;;=C91.41^^45^431^83
;;^UTILITY(U,$J,358.3,8983,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8983,1,3,0)
;;=3^Hairy Cell Leukemia,In Remission
;;^UTILITY(U,$J,358.3,8983,1,4,0)
;;=4^C91.41
;;^UTILITY(U,$J,358.3,8983,2)
;;=^5001772
;;^UTILITY(U,$J,358.3,8984,0)
;;=D57.01^^45^431^85
;;^UTILITY(U,$J,358.3,8984,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8984,1,3,0)
;;=3^Hb-SS Disease w/ Acute Chest Syndrome
;;^UTILITY(U,$J,358.3,8984,1,4,0)
;;=4^D57.01
;;^UTILITY(U,$J,358.3,8984,2)
;;=^5002307
;;^UTILITY(U,$J,358.3,8985,0)
;;=D57.00^^45^431^86
;;^UTILITY(U,$J,358.3,8985,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8985,1,3,0)
;;=3^Hb-SS Disease w/ Crisis,Unspec
;;^UTILITY(U,$J,358.3,8985,1,4,0)
;;=4^D57.00
;;^UTILITY(U,$J,358.3,8985,2)
;;=^5002306
;;^UTILITY(U,$J,358.3,8986,0)
;;=D57.02^^45^431^87
;;^UTILITY(U,$J,358.3,8986,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8986,1,3,0)
;;=3^Hb-SS Disease w/ Splenic Sequestration
;;^UTILITY(U,$J,358.3,8986,1,4,0)
;;=4^D57.02
;;^UTILITY(U,$J,358.3,8986,2)
;;=^5002308
;;^UTILITY(U,$J,358.3,8987,0)
;;=D68.32^^45^431^89
;;^UTILITY(U,$J,358.3,8987,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8987,1,3,0)
;;=3^Hemorrhagic Disorder d/t Extrinsic Circulating Anticoagulants
;;^UTILITY(U,$J,358.3,8987,1,4,0)
;;=4^D68.32
;;^UTILITY(U,$J,358.3,8987,2)
;;=^5002357
;;^UTILITY(U,$J,358.3,8988,0)
;;=C22.2^^45^431^90
;;^UTILITY(U,$J,358.3,8988,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8988,1,3,0)
;;=3^Hepatoblastoma
;;^UTILITY(U,$J,358.3,8988,1,4,0)
;;=4^C22.2
;;^UTILITY(U,$J,358.3,8988,2)
;;=^5000935
;;^UTILITY(U,$J,358.3,8989,0)
;;=D58.9^^45^431^92
;;^UTILITY(U,$J,358.3,8989,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8989,1,3,0)
;;=3^Hereditary Hemolytic Anemia,Unspec
;;^UTILITY(U,$J,358.3,8989,1,4,0)
;;=4^D58.9
;;^UTILITY(U,$J,358.3,8989,2)
;;=^5002322
;;^UTILITY(U,$J,358.3,8990,0)
;;=C81.99^^45^431^93
;;^UTILITY(U,$J,358.3,8990,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8990,1,3,0)
;;=3^Hodgkin Lymphoma,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,8990,1,4,0)
;;=4^C81.99
;;^UTILITY(U,$J,358.3,8990,2)
;;=^5001460
;;^UTILITY(U,$J,358.3,8991,0)
;;=C81.90^^45^431^94
;;^UTILITY(U,$J,358.3,8991,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8991,1,3,0)
;;=3^Hodgkin Lymphoma,Unspec Site
;;^UTILITY(U,$J,358.3,8991,1,4,0)
;;=4^C81.90
;;^UTILITY(U,$J,358.3,8991,2)
;;=^5001451
;;^UTILITY(U,$J,358.3,8992,0)
;;=D89.2^^45^431^95
;;^UTILITY(U,$J,358.3,8992,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8992,1,3,0)
;;=3^Hypergammaglobulenemia,Unspec
;;^UTILITY(U,$J,358.3,8992,1,4,0)
;;=4^D89.2
;;^UTILITY(U,$J,358.3,8992,2)
;;=^5002455
;;^UTILITY(U,$J,358.3,8993,0)
;;=D05.12^^45^431^98
;;^UTILITY(U,$J,358.3,8993,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8993,1,3,0)
;;=3^Intraductal Carcinoma in Situ,Left Breast
;;^UTILITY(U,$J,358.3,8993,1,4,0)
;;=4^D05.12
;;^UTILITY(U,$J,358.3,8993,2)
;;=^5001931
;;^UTILITY(U,$J,358.3,8994,0)
;;=D05.11^^45^431^99
;;^UTILITY(U,$J,358.3,8994,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8994,1,3,0)
;;=3^Intraductal Carcinoma in Situ,Right Breast
;;^UTILITY(U,$J,358.3,8994,1,4,0)
;;=4^D05.11
;;^UTILITY(U,$J,358.3,8994,2)
;;=^5001930
;;^UTILITY(U,$J,358.3,8995,0)
;;=D05.10^^45^431^100
;;^UTILITY(U,$J,358.3,8995,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8995,1,3,0)
;;=3^Intraductal Carcinoma in Situ,Unspec Breast
;;^UTILITY(U,$J,358.3,8995,1,4,0)
;;=4^D05.10
;;^UTILITY(U,$J,358.3,8995,2)
;;=^5001929
;;^UTILITY(U,$J,358.3,8996,0)
;;=D50.0^^45^431^101
;;^UTILITY(U,$J,358.3,8996,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8996,1,3,0)
;;=3^Iron Deficiency Anemia Secondary to Blood Loss
;;^UTILITY(U,$J,358.3,8996,1,4,0)
;;=4^D50.0
;;^UTILITY(U,$J,358.3,8996,2)
;;=^267971
;;^UTILITY(U,$J,358.3,8997,0)
;;=D50.9^^45^431^102
;;^UTILITY(U,$J,358.3,8997,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8997,1,3,0)
;;=3^Iron Deficiency Anemia,Unspec
;;^UTILITY(U,$J,358.3,8997,1,4,0)
;;=4^D50.9
;;^UTILITY(U,$J,358.3,8997,2)
;;=^5002283
;;^UTILITY(U,$J,358.3,8998,0)
;;=C46.9^^45^431^103
;;^UTILITY(U,$J,358.3,8998,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8998,1,3,0)
;;=3^Kaposi's Sarcoma,Unspec
;;^UTILITY(U,$J,358.3,8998,1,4,0)
;;=4^C46.9
;;^UTILITY(U,$J,358.3,8998,2)
;;=^5001108
;;^UTILITY(U,$J,358.3,8999,0)
;;=C22.0^^45^431^104
;;^UTILITY(U,$J,358.3,8999,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8999,1,3,0)
;;=3^Liver Cell Carcinoma
;;^UTILITY(U,$J,358.3,8999,1,4,0)
;;=4^C22.0
;;^UTILITY(U,$J,358.3,8999,2)
;;=^5000933
;;^UTILITY(U,$J,358.3,9000,0)
;;=D05.02^^45^431^105
;;^UTILITY(U,$J,358.3,9000,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,9000,1,3,0)
;;=3^Lobular Carcinoma in Situ,Left Breast
;;^UTILITY(U,$J,358.3,9000,1,4,0)
;;=4^D05.02
;;^UTILITY(U,$J,358.3,9000,2)
;;=^5001928
;;^UTILITY(U,$J,358.3,9001,0)
;;=D05.01^^45^431^106
;;^UTILITY(U,$J,358.3,9001,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,9001,1,3,0)
;;=3^Lobular Carcinoma in Situ,Right Breast
;;^UTILITY(U,$J,358.3,9001,1,4,0)
;;=4^D05.01
;;^UTILITY(U,$J,358.3,9001,2)
;;=^5001927
;;^UTILITY(U,$J,358.3,9002,0)
;;=D05.00^^45^431^107
;;^UTILITY(U,$J,358.3,9002,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,9002,1,3,0)
;;=3^Lobular Carcinoma in Situ,Unspec Breast
;;^UTILITY(U,$J,358.3,9002,1,4,0)
;;=4^D05.00
;;^UTILITY(U,$J,358.3,9002,2)
;;=^5001926
;;^UTILITY(U,$J,358.3,9003,0)
;;=R59.0^^45^431^66
;;^UTILITY(U,$J,358.3,9003,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,9003,1,3,0)
;;=3^Enlarged Lymph Nodes,Localized
;;^UTILITY(U,$J,358.3,9003,1,4,0)
;;=4^R59.0
;;^UTILITY(U,$J,358.3,9003,2)
;;=^5019529
;;^UTILITY(U,$J,358.3,9004,0)
;;=C83.59^^45^431^108
;;^UTILITY(U,$J,358.3,9004,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,9004,1,3,0)
;;=3^Lymphoblastic Lymphoma,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,9004,1,4,0)
;;=4^C83.59
;;^UTILITY(U,$J,358.3,9004,2)
;;=^5001590
;;^UTILITY(U,$J,358.3,9005,0)
;;=C83.50^^45^431^109
;;^UTILITY(U,$J,358.3,9005,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,9005,1,3,0)
;;=3^Lymphoblastic Lymphoma,Unspec Site
;;^UTILITY(U,$J,358.3,9005,1,4,0)
;;=4^C83.50
;;^UTILITY(U,$J,358.3,9005,2)
;;=^5001581
;;^UTILITY(U,$J,358.3,9006,0)
;;=C43.9^^45^431^112
;;^UTILITY(U,$J,358.3,9006,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,9006,1,3,0)
;;=3^Malig Melanoma of Skin,Unspec Site
;;^UTILITY(U,$J,358.3,9006,1,4,0)
;;=4^C43.9
;;^UTILITY(U,$J,358.3,9006,2)
;;=^5001015
;;^UTILITY(U,$J,358.3,9007,0)
;;=C31.9^^45^431^113
;;^UTILITY(U,$J,358.3,9007,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,9007,1,3,0)
;;=3^Malig Neop Accessory Sinus,Unspec
;;^UTILITY(U,$J,358.3,9007,1,4,0)
;;=4^C31.9
;;^UTILITY(U,$J,358.3,9007,2)
;;=^5000953
;;^UTILITY(U,$J,358.3,9008,0)
;;=C24.1^^45^431^115
;;^UTILITY(U,$J,358.3,9008,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,9008,1,3,0)
;;=3^Malig Neop Ampulla of Vater
;;^UTILITY(U,$J,358.3,9008,1,4,0)
;;=4^C24.1
;;^UTILITY(U,$J,358.3,9008,2)
;;=^267100
;;^UTILITY(U,$J,358.3,9009,0)
;;=C21.0^^45^431^116
;;^UTILITY(U,$J,358.3,9009,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,9009,1,3,0)
;;=3^Malig Neop Anus,Unspec
;;^UTILITY(U,$J,358.3,9009,1,4,0)
;;=4^C21.0
;;^UTILITY(U,$J,358.3,9009,2)
;;=^5000930
;;^UTILITY(U,$J,358.3,9010,0)
;;=C67.9^^45^431^119
;;^UTILITY(U,$J,358.3,9010,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,9010,1,3,0)
;;=3^Malig Neop Bladder,Unspec
;;^UTILITY(U,$J,358.3,9010,1,4,0)
;;=4^C67.9
;;^UTILITY(U,$J,358.3,9010,2)
;;=^5001263
;;^UTILITY(U,$J,358.3,9011,0)
;;=C71.9^^45^431^123
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI03Q 19794 printed Apr 09, 2024@21:00:07 Page 2
IBDEI03Q ; ; 01-AUG-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,8942,1,4,0)
+2 ;;=4^D63.0
+3 ;;^UTILITY(U,$J,358.3,8942,2)
+4 ;;=^321978
+5 ;;^UTILITY(U,$J,358.3,8943,0)
+6 ;;=D63.8^^45^431^22
+7 ;;^UTILITY(U,$J,358.3,8943,1,0)
+8 ;;=^358.31IA^4^2
+9 ;;^UTILITY(U,$J,358.3,8943,1,3,0)
+10 ;;=3^Anemia in Chronic Diseases Classified Elsewhere
+11 ;;^UTILITY(U,$J,358.3,8943,1,4,0)
+12 ;;=4^D63.8
+13 ;;^UTILITY(U,$J,358.3,8943,2)
+14 ;;=^5002343
+15 ;;^UTILITY(U,$J,358.3,8944,0)
+16 ;;=C22.3^^45^431^27
+17 ;;^UTILITY(U,$J,358.3,8944,1,0)
+18 ;;=^358.31IA^4^2
+19 ;;^UTILITY(U,$J,358.3,8944,1,3,0)
+20 ;;=3^Angiosarcoma of Liver
+21 ;;^UTILITY(U,$J,358.3,8944,1,4,0)
+22 ;;=4^C22.3
+23 ;;^UTILITY(U,$J,358.3,8944,2)
+24 ;;=^5000936
+25 ;;^UTILITY(U,$J,358.3,8945,0)
+26 ;;=D61.9^^45^431^28
+27 ;;^UTILITY(U,$J,358.3,8945,1,0)
+28 ;;=^358.31IA^4^2
+29 ;;^UTILITY(U,$J,358.3,8945,1,3,0)
+30 ;;=3^Aplastic Anemia,Unspec
+31 ;;^UTILITY(U,$J,358.3,8945,1,4,0)
+32 ;;=4^D61.9
+33 ;;^UTILITY(U,$J,358.3,8945,2)
+34 ;;=^5002342
+35 ;;^UTILITY(U,$J,358.3,8946,0)
+36 ;;=D56.1^^45^431^34
+37 ;;^UTILITY(U,$J,358.3,8946,1,0)
+38 ;;=^358.31IA^4^2
+39 ;;^UTILITY(U,$J,358.3,8946,1,3,0)
+40 ;;=3^Beta Thalassemia
+41 ;;^UTILITY(U,$J,358.3,8946,1,4,0)
+42 ;;=4^D56.1
+43 ;;^UTILITY(U,$J,358.3,8946,2)
+44 ;;=^340495
+45 ;;^UTILITY(U,$J,358.3,8947,0)
+46 ;;=C83.79^^45^431^36
+47 ;;^UTILITY(U,$J,358.3,8947,1,0)
+48 ;;=^358.31IA^4^2
+49 ;;^UTILITY(U,$J,358.3,8947,1,3,0)
+50 ;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
+51 ;;^UTILITY(U,$J,358.3,8947,1,4,0)
+52 ;;=4^C83.79
+53 ;;^UTILITY(U,$J,358.3,8947,2)
+54 ;;=^5001600
+55 ;;^UTILITY(U,$J,358.3,8948,0)
+56 ;;=C83.70^^45^431^37
+57 ;;^UTILITY(U,$J,358.3,8948,1,0)
+58 ;;=^358.31IA^4^2
+59 ;;^UTILITY(U,$J,358.3,8948,1,3,0)
+60 ;;=3^Burkitt Lymphoma,Unspec Site
+61 ;;^UTILITY(U,$J,358.3,8948,1,4,0)
+62 ;;=4^C83.70
+63 ;;^UTILITY(U,$J,358.3,8948,2)
+64 ;;=^5001591
+65 ;;^UTILITY(U,$J,358.3,8949,0)
+66 ;;=D09.0^^45^431^44
+67 ;;^UTILITY(U,$J,358.3,8949,1,0)
+68 ;;=^358.31IA^4^2
+69 ;;^UTILITY(U,$J,358.3,8949,1,3,0)
+70 ;;=3^Carcinoma in Situ of Bladder
+71 ;;^UTILITY(U,$J,358.3,8949,1,4,0)
+72 ;;=4^D09.0
+73 ;;^UTILITY(U,$J,358.3,8949,2)
+74 ;;=^267742
+75 ;;^UTILITY(U,$J,358.3,8950,0)
+76 ;;=D06.9^^45^431^45
+77 ;;^UTILITY(U,$J,358.3,8950,1,0)
+78 ;;=^358.31IA^4^2
+79 ;;^UTILITY(U,$J,358.3,8950,1,3,0)
+80 ;;=3^Carcinoma in Situ of Cervix
+81 ;;^UTILITY(U,$J,358.3,8950,1,4,0)
+82 ;;=4^D06.9
+83 ;;^UTILITY(U,$J,358.3,8950,2)
+84 ;;=^5001941
+85 ;;^UTILITY(U,$J,358.3,8951,0)
+86 ;;=D06.0^^45^431^47
+87 ;;^UTILITY(U,$J,358.3,8951,1,0)
+88 ;;=^358.31IA^4^2
+89 ;;^UTILITY(U,$J,358.3,8951,1,3,0)
+90 ;;=3^Carcinoma in Situ of Endocervix
+91 ;;^UTILITY(U,$J,358.3,8951,1,4,0)
+92 ;;=4^D06.0
+93 ;;^UTILITY(U,$J,358.3,8951,2)
+94 ;;=^5001938
+95 ;;^UTILITY(U,$J,358.3,8952,0)
+96 ;;=D06.1^^45^431^48
+97 ;;^UTILITY(U,$J,358.3,8952,1,0)
+98 ;;=^358.31IA^4^2
+99 ;;^UTILITY(U,$J,358.3,8952,1,3,0)
+100 ;;=3^Carcinoma in Situ of Exocervix
+101 ;;^UTILITY(U,$J,358.3,8952,1,4,0)
+102 ;;=4^D06.1
+103 ;;^UTILITY(U,$J,358.3,8952,2)
+104 ;;=^5001939
+105 ;;^UTILITY(U,$J,358.3,8953,0)
+106 ;;=D06.7^^45^431^46
+107 ;;^UTILITY(U,$J,358.3,8953,1,0)
+108 ;;=^358.31IA^4^2
+109 ;;^UTILITY(U,$J,358.3,8953,1,3,0)
+110 ;;=3^Carcinoma in Situ of Cervix,Other Parts
+111 ;;^UTILITY(U,$J,358.3,8953,1,4,0)
+112 ;;=4^D06.7
+113 ;;^UTILITY(U,$J,358.3,8953,2)
+114 ;;=^5001940
+115 ;;^UTILITY(U,$J,358.3,8954,0)
+116 ;;=D04.9^^45^431^49
+117 ;;^UTILITY(U,$J,358.3,8954,1,0)
+118 ;;=^358.31IA^4^2
+119 ;;^UTILITY(U,$J,358.3,8954,1,3,0)
+120 ;;=3^Carcinoma in Situ of Skin
+121 ;;^UTILITY(U,$J,358.3,8954,1,4,0)
+122 ;;=4^D04.9
+123 ;;^UTILITY(U,$J,358.3,8954,2)
+124 ;;=^5001925
+125 ;;^UTILITY(U,$J,358.3,8955,0)
+126 ;;=C91.11^^45^431^52
+127 ;;^UTILITY(U,$J,358.3,8955,1,0)
+128 ;;=^358.31IA^4^2
+129 ;;^UTILITY(U,$J,358.3,8955,1,3,0)
+130 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
+131 ;;^UTILITY(U,$J,358.3,8955,1,4,0)
+132 ;;=4^C91.11
+133 ;;^UTILITY(U,$J,358.3,8955,2)
+134 ;;=^5001766
+135 ;;^UTILITY(U,$J,358.3,8956,0)
+136 ;;=C91.10^^45^431^53
+137 ;;^UTILITY(U,$J,358.3,8956,1,0)
+138 ;;=^358.31IA^4^2
+139 ;;^UTILITY(U,$J,358.3,8956,1,3,0)
+140 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
+141 ;;^UTILITY(U,$J,358.3,8956,1,4,0)
+142 ;;=4^C91.10
+143 ;;^UTILITY(U,$J,358.3,8956,2)
+144 ;;=^5001765
+145 ;;^UTILITY(U,$J,358.3,8957,0)
+146 ;;=C92.11^^45^431^54
+147 ;;^UTILITY(U,$J,358.3,8957,1,0)
+148 ;;=^358.31IA^4^2
+149 ;;^UTILITY(U,$J,358.3,8957,1,3,0)
+150 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
+151 ;;^UTILITY(U,$J,358.3,8957,1,4,0)
+152 ;;=4^C92.11
+153 ;;^UTILITY(U,$J,358.3,8957,2)
+154 ;;=^5001793
+155 ;;^UTILITY(U,$J,358.3,8958,0)
+156 ;;=C92.10^^45^431^55
+157 ;;^UTILITY(U,$J,358.3,8958,1,0)
+158 ;;=^358.31IA^4^2
+159 ;;^UTILITY(U,$J,358.3,8958,1,3,0)
+160 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
+161 ;;^UTILITY(U,$J,358.3,8958,1,4,0)
+162 ;;=4^C92.10
+163 ;;^UTILITY(U,$J,358.3,8958,2)
+164 ;;=^5001792
+165 ;;^UTILITY(U,$J,358.3,8959,0)
+166 ;;=D47.1^^45^431^56
+167 ;;^UTILITY(U,$J,358.3,8959,1,0)
+168 ;;=^358.31IA^4^2
+169 ;;^UTILITY(U,$J,358.3,8959,1,3,0)
+170 ;;=3^Chronic Myeloproliferative Disease
+171 ;;^UTILITY(U,$J,358.3,8959,1,4,0)
+172 ;;=4^D47.1
+173 ;;^UTILITY(U,$J,358.3,8959,2)
+174 ;;=^5002256
+175 ;;^UTILITY(U,$J,358.3,8960,0)
+176 ;;=C82.69^^45^431^57
+177 ;;^UTILITY(U,$J,358.3,8960,1,0)
+178 ;;=^358.31IA^4^2
+179 ;;^UTILITY(U,$J,358.3,8960,1,3,0)
+180 ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
+181 ;;^UTILITY(U,$J,358.3,8960,1,4,0)
+182 ;;=4^C82.69
+183 ;;^UTILITY(U,$J,358.3,8960,2)
+184 ;;=^5001530
+185 ;;^UTILITY(U,$J,358.3,8961,0)
+186 ;;=C82.60^^45^431^58
+187 ;;^UTILITY(U,$J,358.3,8961,1,0)
+188 ;;=^358.31IA^4^2
+189 ;;^UTILITY(U,$J,358.3,8961,1,3,0)
+190 ;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
+191 ;;^UTILITY(U,$J,358.3,8961,1,4,0)
+192 ;;=4^C82.60
+193 ;;^UTILITY(U,$J,358.3,8961,2)
+194 ;;=^5001521
+195 ;;^UTILITY(U,$J,358.3,8962,0)
+196 ;;=D56.2^^45^431^59
+197 ;;^UTILITY(U,$J,358.3,8962,1,0)
+198 ;;=^358.31IA^4^2
+199 ;;^UTILITY(U,$J,358.3,8962,1,3,0)
+200 ;;=3^Delta-Beta Thalassemia
+201 ;;^UTILITY(U,$J,358.3,8962,1,4,0)
+202 ;;=4^D56.2
+203 ;;^UTILITY(U,$J,358.3,8962,2)
+204 ;;=^340496
+205 ;;^UTILITY(U,$J,358.3,8963,0)
+206 ;;=D75.9^^45^431^60
+207 ;;^UTILITY(U,$J,358.3,8963,1,0)
+208 ;;=^358.31IA^4^2
+209 ;;^UTILITY(U,$J,358.3,8963,1,3,0)
+210 ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
+211 ;;^UTILITY(U,$J,358.3,8963,1,4,0)
+212 ;;=4^D75.9
+213 ;;^UTILITY(U,$J,358.3,8963,2)
+214 ;;=^5002393
+215 ;;^UTILITY(U,$J,358.3,8964,0)
+216 ;;=D59.0^^45^431^63
+217 ;;^UTILITY(U,$J,358.3,8964,1,0)
+218 ;;=^358.31IA^4^2
+219 ;;^UTILITY(U,$J,358.3,8964,1,3,0)
+220 ;;=3^Drug-Induced Autoimmune Hemolytic Anemia
+221 ;;^UTILITY(U,$J,358.3,8964,1,4,0)
+222 ;;=4^D59.0
+223 ;;^UTILITY(U,$J,358.3,8964,2)
+224 ;;=^5002323
+225 ;;^UTILITY(U,$J,358.3,8965,0)
+226 ;;=D59.2^^45^431^64
+227 ;;^UTILITY(U,$J,358.3,8965,1,0)
+228 ;;=^358.31IA^4^2
+229 ;;^UTILITY(U,$J,358.3,8965,1,3,0)
+230 ;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
+231 ;;^UTILITY(U,$J,358.3,8965,1,4,0)
+232 ;;=4^D59.2
+233 ;;^UTILITY(U,$J,358.3,8965,2)
+234 ;;=^5002325
+235 ;;^UTILITY(U,$J,358.3,8966,0)
+236 ;;=R59.9^^45^431^67
+237 ;;^UTILITY(U,$J,358.3,8966,1,0)
+238 ;;=^358.31IA^4^2
+239 ;;^UTILITY(U,$J,358.3,8966,1,3,0)
+240 ;;=3^Enlarged Lymph Nodes,Unspec
+241 ;;^UTILITY(U,$J,358.3,8966,1,4,0)
+242 ;;=4^R59.9
+243 ;;^UTILITY(U,$J,358.3,8966,2)
+244 ;;=^5019531
+245 ;;^UTILITY(U,$J,358.3,8967,0)
+246 ;;=D47.3^^45^431^68
+247 ;;^UTILITY(U,$J,358.3,8967,1,0)
+248 ;;=^358.31IA^4^2
+249 ;;^UTILITY(U,$J,358.3,8967,1,3,0)
+250 ;;=3^Essential Thrombocythemia
+251 ;;^UTILITY(U,$J,358.3,8967,1,4,0)
+252 ;;=4^D47.3
+253 ;;^UTILITY(U,$J,358.3,8967,2)
+254 ;;=^5002258
+255 ;;^UTILITY(U,$J,358.3,8968,0)
+256 ;;=C82.09^^45^431^69
+257 ;;^UTILITY(U,$J,358.3,8968,1,0)
+258 ;;=^358.31IA^4^2
+259 ;;^UTILITY(U,$J,358.3,8968,1,3,0)
+260 ;;=3^Follicular Lymphoma Grade I,Extranodal/Solid Organ Sites
+261 ;;^UTILITY(U,$J,358.3,8968,1,4,0)
+262 ;;=4^C82.09
+263 ;;^UTILITY(U,$J,358.3,8968,2)
+264 ;;=^5001470
+265 ;;^UTILITY(U,$J,358.3,8969,0)
+266 ;;=C82.00^^45^431^70
+267 ;;^UTILITY(U,$J,358.3,8969,1,0)
+268 ;;=^358.31IA^4^2
+269 ;;^UTILITY(U,$J,358.3,8969,1,3,0)
+270 ;;=3^Follicular Lymphoma Grade I,Unspec Site
+271 ;;^UTILITY(U,$J,358.3,8969,1,4,0)
+272 ;;=4^C82.00
+273 ;;^UTILITY(U,$J,358.3,8969,2)
+274 ;;=^5001461
+275 ;;^UTILITY(U,$J,358.3,8970,0)
+276 ;;=C82.19^^45^431^71
+277 ;;^UTILITY(U,$J,358.3,8970,1,0)
+278 ;;=^358.31IA^4^2
+279 ;;^UTILITY(U,$J,358.3,8970,1,3,0)
+280 ;;=3^Follicular Lymphoma Grade II,Extranodal/Solid Organ Sites
+281 ;;^UTILITY(U,$J,358.3,8970,1,4,0)
+282 ;;=4^C82.19
+283 ;;^UTILITY(U,$J,358.3,8970,2)
+284 ;;=^5001480
+285 ;;^UTILITY(U,$J,358.3,8971,0)
+286 ;;=C82.10^^45^431^72
+287 ;;^UTILITY(U,$J,358.3,8971,1,0)
+288 ;;=^358.31IA^4^2
+289 ;;^UTILITY(U,$J,358.3,8971,1,3,0)
+290 ;;=3^Follicular Lymphoma Grade II,Unspec Site
+291 ;;^UTILITY(U,$J,358.3,8971,1,4,0)
+292 ;;=4^C82.10
+293 ;;^UTILITY(U,$J,358.3,8971,2)
+294 ;;=^5001471
+295 ;;^UTILITY(U,$J,358.3,8972,0)
+296 ;;=C82.29^^45^431^73
+297 ;;^UTILITY(U,$J,358.3,8972,1,0)
+298 ;;=^358.31IA^4^2
+299 ;;^UTILITY(U,$J,358.3,8972,1,3,0)
+300 ;;=3^Follicular Lymphoma Grade III,Extranodal/Solid Organ Sites
+301 ;;^UTILITY(U,$J,358.3,8972,1,4,0)
+302 ;;=4^C82.29
+303 ;;^UTILITY(U,$J,358.3,8972,2)
+304 ;;=^5001490
+305 ;;^UTILITY(U,$J,358.3,8973,0)
+306 ;;=C82.20^^45^431^74
+307 ;;^UTILITY(U,$J,358.3,8973,1,0)
+308 ;;=^358.31IA^4^2
+309 ;;^UTILITY(U,$J,358.3,8973,1,3,0)
+310 ;;=3^Follicular Lymphoma Grade III,Unspec Site
+311 ;;^UTILITY(U,$J,358.3,8973,1,4,0)
+312 ;;=4^C82.20
+313 ;;^UTILITY(U,$J,358.3,8973,2)
+314 ;;=^5001481
+315 ;;^UTILITY(U,$J,358.3,8974,0)
+316 ;;=C82.39^^45^431^75
+317 ;;^UTILITY(U,$J,358.3,8974,1,0)
+318 ;;=^358.31IA^4^2
+319 ;;^UTILITY(U,$J,358.3,8974,1,3,0)
+320 ;;=3^Follicular Lymphoma Grade IIIa,Extranodal/Solid Organ Sites
+321 ;;^UTILITY(U,$J,358.3,8974,1,4,0)
+322 ;;=4^C82.39
+323 ;;^UTILITY(U,$J,358.3,8974,2)
+324 ;;=^5001500
+325 ;;^UTILITY(U,$J,358.3,8975,0)
+326 ;;=C82.30^^45^431^76
+327 ;;^UTILITY(U,$J,358.3,8975,1,0)
+328 ;;=^358.31IA^4^2
+329 ;;^UTILITY(U,$J,358.3,8975,1,3,0)
+330 ;;=3^Follicular Lymphoma Grade IIIa,Unspec Site
+331 ;;^UTILITY(U,$J,358.3,8975,1,4,0)
+332 ;;=4^C82.30
+333 ;;^UTILITY(U,$J,358.3,8975,2)
+334 ;;=^5001491
+335 ;;^UTILITY(U,$J,358.3,8976,0)
+336 ;;=C82.49^^45^431^77
+337 ;;^UTILITY(U,$J,358.3,8976,1,0)
+338 ;;=^358.31IA^4^2
+339 ;;^UTILITY(U,$J,358.3,8976,1,3,0)
+340 ;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
+341 ;;^UTILITY(U,$J,358.3,8976,1,4,0)
+342 ;;=4^C82.49
+343 ;;^UTILITY(U,$J,358.3,8976,2)
+344 ;;=^5001510
+345 ;;^UTILITY(U,$J,358.3,8977,0)
+346 ;;=C82.40^^45^431^78
+347 ;;^UTILITY(U,$J,358.3,8977,1,0)
+348 ;;=^358.31IA^4^2
+349 ;;^UTILITY(U,$J,358.3,8977,1,3,0)
+350 ;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
+351 ;;^UTILITY(U,$J,358.3,8977,1,4,0)
+352 ;;=4^C82.40
+353 ;;^UTILITY(U,$J,358.3,8977,2)
+354 ;;=^5001501
+355 ;;^UTILITY(U,$J,358.3,8978,0)
+356 ;;=C82.99^^45^431^79
+357 ;;^UTILITY(U,$J,358.3,8978,1,0)
+358 ;;=^358.31IA^4^2
+359 ;;^UTILITY(U,$J,358.3,8978,1,3,0)
+360 ;;=3^Follicular Lymphoma Unspec,Extranodal/Solid Organ Sites
+361 ;;^UTILITY(U,$J,358.3,8978,1,4,0)
+362 ;;=4^C82.99
+363 ;;^UTILITY(U,$J,358.3,8978,2)
+364 ;;=^5001550
+365 ;;^UTILITY(U,$J,358.3,8979,0)
+366 ;;=C82.90^^45^431^80
+367 ;;^UTILITY(U,$J,358.3,8979,1,0)
+368 ;;=^358.31IA^4^2
+369 ;;^UTILITY(U,$J,358.3,8979,1,3,0)
+370 ;;=3^Follicular Lymphoma Unspec,Unspec Site
+371 ;;^UTILITY(U,$J,358.3,8979,1,4,0)
+372 ;;=4^C82.90
+373 ;;^UTILITY(U,$J,358.3,8979,2)
+374 ;;=^5001541
+375 ;;^UTILITY(U,$J,358.3,8980,0)
+376 ;;=R59.1^^45^431^65
+377 ;;^UTILITY(U,$J,358.3,8980,1,0)
+378 ;;=^358.31IA^4^2
+379 ;;^UTILITY(U,$J,358.3,8980,1,3,0)
+380 ;;=3^Enlarged Lymph Nodes,Generalized
+381 ;;^UTILITY(U,$J,358.3,8980,1,4,0)
+382 ;;=4^R59.1
+383 ;;^UTILITY(U,$J,358.3,8980,2)
+384 ;;=^5019530
+385 ;;^UTILITY(U,$J,358.3,8981,0)
+386 ;;=C91.40^^45^431^84
+387 ;;^UTILITY(U,$J,358.3,8981,1,0)
+388 ;;=^358.31IA^4^2
+389 ;;^UTILITY(U,$J,358.3,8981,1,3,0)
+390 ;;=3^Hairy Cell Leukemia,Not in Remission
+391 ;;^UTILITY(U,$J,358.3,8981,1,4,0)
+392 ;;=4^C91.40
+393 ;;^UTILITY(U,$J,358.3,8981,2)
+394 ;;=^5001771
+395 ;;^UTILITY(U,$J,358.3,8982,0)
+396 ;;=C91.42^^45^431^82
+397 ;;^UTILITY(U,$J,358.3,8982,1,0)
+398 ;;=^358.31IA^4^2
+399 ;;^UTILITY(U,$J,358.3,8982,1,3,0)
+400 ;;=3^Hairy Cell Leukemia,In Relapse
+401 ;;^UTILITY(U,$J,358.3,8982,1,4,0)
+402 ;;=4^C91.42
+403 ;;^UTILITY(U,$J,358.3,8982,2)
+404 ;;=^5001773
+405 ;;^UTILITY(U,$J,358.3,8983,0)
+406 ;;=C91.41^^45^431^83
+407 ;;^UTILITY(U,$J,358.3,8983,1,0)
+408 ;;=^358.31IA^4^2
+409 ;;^UTILITY(U,$J,358.3,8983,1,3,0)
+410 ;;=3^Hairy Cell Leukemia,In Remission
+411 ;;^UTILITY(U,$J,358.3,8983,1,4,0)
+412 ;;=4^C91.41
+413 ;;^UTILITY(U,$J,358.3,8983,2)
+414 ;;=^5001772
+415 ;;^UTILITY(U,$J,358.3,8984,0)
+416 ;;=D57.01^^45^431^85
+417 ;;^UTILITY(U,$J,358.3,8984,1,0)
+418 ;;=^358.31IA^4^2
+419 ;;^UTILITY(U,$J,358.3,8984,1,3,0)
+420 ;;=3^Hb-SS Disease w/ Acute Chest Syndrome
+421 ;;^UTILITY(U,$J,358.3,8984,1,4,0)
+422 ;;=4^D57.01
+423 ;;^UTILITY(U,$J,358.3,8984,2)
+424 ;;=^5002307
+425 ;;^UTILITY(U,$J,358.3,8985,0)
+426 ;;=D57.00^^45^431^86
+427 ;;^UTILITY(U,$J,358.3,8985,1,0)
+428 ;;=^358.31IA^4^2
+429 ;;^UTILITY(U,$J,358.3,8985,1,3,0)
+430 ;;=3^Hb-SS Disease w/ Crisis,Unspec
+431 ;;^UTILITY(U,$J,358.3,8985,1,4,0)
+432 ;;=4^D57.00
+433 ;;^UTILITY(U,$J,358.3,8985,2)
+434 ;;=^5002306
+435 ;;^UTILITY(U,$J,358.3,8986,0)
+436 ;;=D57.02^^45^431^87
+437 ;;^UTILITY(U,$J,358.3,8986,1,0)
+438 ;;=^358.31IA^4^2
+439 ;;^UTILITY(U,$J,358.3,8986,1,3,0)
+440 ;;=3^Hb-SS Disease w/ Splenic Sequestration
+441 ;;^UTILITY(U,$J,358.3,8986,1,4,0)
+442 ;;=4^D57.02
+443 ;;^UTILITY(U,$J,358.3,8986,2)
+444 ;;=^5002308
+445 ;;^UTILITY(U,$J,358.3,8987,0)
+446 ;;=D68.32^^45^431^89
+447 ;;^UTILITY(U,$J,358.3,8987,1,0)
+448 ;;=^358.31IA^4^2
+449 ;;^UTILITY(U,$J,358.3,8987,1,3,0)
+450 ;;=3^Hemorrhagic Disorder d/t Extrinsic Circulating Anticoagulants
+451 ;;^UTILITY(U,$J,358.3,8987,1,4,0)
+452 ;;=4^D68.32
+453 ;;^UTILITY(U,$J,358.3,8987,2)
+454 ;;=^5002357
+455 ;;^UTILITY(U,$J,358.3,8988,0)
+456 ;;=C22.2^^45^431^90
+457 ;;^UTILITY(U,$J,358.3,8988,1,0)
+458 ;;=^358.31IA^4^2
+459 ;;^UTILITY(U,$J,358.3,8988,1,3,0)
+460 ;;=3^Hepatoblastoma
+461 ;;^UTILITY(U,$J,358.3,8988,1,4,0)
+462 ;;=4^C22.2
+463 ;;^UTILITY(U,$J,358.3,8988,2)
+464 ;;=^5000935
+465 ;;^UTILITY(U,$J,358.3,8989,0)
+466 ;;=D58.9^^45^431^92
+467 ;;^UTILITY(U,$J,358.3,8989,1,0)
+468 ;;=^358.31IA^4^2
+469 ;;^UTILITY(U,$J,358.3,8989,1,3,0)
+470 ;;=3^Hereditary Hemolytic Anemia,Unspec
+471 ;;^UTILITY(U,$J,358.3,8989,1,4,0)
+472 ;;=4^D58.9
+473 ;;^UTILITY(U,$J,358.3,8989,2)
+474 ;;=^5002322
+475 ;;^UTILITY(U,$J,358.3,8990,0)
+476 ;;=C81.99^^45^431^93
+477 ;;^UTILITY(U,$J,358.3,8990,1,0)
+478 ;;=^358.31IA^4^2
+479 ;;^UTILITY(U,$J,358.3,8990,1,3,0)
+480 ;;=3^Hodgkin Lymphoma,Extranodal/Solid Organ Sites
+481 ;;^UTILITY(U,$J,358.3,8990,1,4,0)
+482 ;;=4^C81.99
+483 ;;^UTILITY(U,$J,358.3,8990,2)
+484 ;;=^5001460
+485 ;;^UTILITY(U,$J,358.3,8991,0)
+486 ;;=C81.90^^45^431^94
+487 ;;^UTILITY(U,$J,358.3,8991,1,0)
+488 ;;=^358.31IA^4^2
+489 ;;^UTILITY(U,$J,358.3,8991,1,3,0)
+490 ;;=3^Hodgkin Lymphoma,Unspec Site
+491 ;;^UTILITY(U,$J,358.3,8991,1,4,0)
+492 ;;=4^C81.90
+493 ;;^UTILITY(U,$J,358.3,8991,2)
+494 ;;=^5001451
+495 ;;^UTILITY(U,$J,358.3,8992,0)
+496 ;;=D89.2^^45^431^95
+497 ;;^UTILITY(U,$J,358.3,8992,1,0)
+498 ;;=^358.31IA^4^2
+499 ;;^UTILITY(U,$J,358.3,8992,1,3,0)
+500 ;;=3^Hypergammaglobulenemia,Unspec
+501 ;;^UTILITY(U,$J,358.3,8992,1,4,0)
+502 ;;=4^D89.2
+503 ;;^UTILITY(U,$J,358.3,8992,2)
+504 ;;=^5002455
+505 ;;^UTILITY(U,$J,358.3,8993,0)
+506 ;;=D05.12^^45^431^98
+507 ;;^UTILITY(U,$J,358.3,8993,1,0)
+508 ;;=^358.31IA^4^2
+509 ;;^UTILITY(U,$J,358.3,8993,1,3,0)
+510 ;;=3^Intraductal Carcinoma in Situ,Left Breast
+511 ;;^UTILITY(U,$J,358.3,8993,1,4,0)
+512 ;;=4^D05.12
+513 ;;^UTILITY(U,$J,358.3,8993,2)
+514 ;;=^5001931
+515 ;;^UTILITY(U,$J,358.3,8994,0)
+516 ;;=D05.11^^45^431^99
+517 ;;^UTILITY(U,$J,358.3,8994,1,0)
+518 ;;=^358.31IA^4^2
+519 ;;^UTILITY(U,$J,358.3,8994,1,3,0)
+520 ;;=3^Intraductal Carcinoma in Situ,Right Breast
+521 ;;^UTILITY(U,$J,358.3,8994,1,4,0)
+522 ;;=4^D05.11
+523 ;;^UTILITY(U,$J,358.3,8994,2)
+524 ;;=^5001930
+525 ;;^UTILITY(U,$J,358.3,8995,0)
+526 ;;=D05.10^^45^431^100
+527 ;;^UTILITY(U,$J,358.3,8995,1,0)
+528 ;;=^358.31IA^4^2
+529 ;;^UTILITY(U,$J,358.3,8995,1,3,0)
+530 ;;=3^Intraductal Carcinoma in Situ,Unspec Breast
+531 ;;^UTILITY(U,$J,358.3,8995,1,4,0)
+532 ;;=4^D05.10
+533 ;;^UTILITY(U,$J,358.3,8995,2)
+534 ;;=^5001929
+535 ;;^UTILITY(U,$J,358.3,8996,0)
+536 ;;=D50.0^^45^431^101
+537 ;;^UTILITY(U,$J,358.3,8996,1,0)
+538 ;;=^358.31IA^4^2
+539 ;;^UTILITY(U,$J,358.3,8996,1,3,0)
+540 ;;=3^Iron Deficiency Anemia Secondary to Blood Loss
+541 ;;^UTILITY(U,$J,358.3,8996,1,4,0)
+542 ;;=4^D50.0
+543 ;;^UTILITY(U,$J,358.3,8996,2)
+544 ;;=^267971
+545 ;;^UTILITY(U,$J,358.3,8997,0)
+546 ;;=D50.9^^45^431^102
+547 ;;^UTILITY(U,$J,358.3,8997,1,0)
+548 ;;=^358.31IA^4^2
+549 ;;^UTILITY(U,$J,358.3,8997,1,3,0)
+550 ;;=3^Iron Deficiency Anemia,Unspec
+551 ;;^UTILITY(U,$J,358.3,8997,1,4,0)
+552 ;;=4^D50.9
+553 ;;^UTILITY(U,$J,358.3,8997,2)
+554 ;;=^5002283
+555 ;;^UTILITY(U,$J,358.3,8998,0)
+556 ;;=C46.9^^45^431^103
+557 ;;^UTILITY(U,$J,358.3,8998,1,0)
+558 ;;=^358.31IA^4^2
+559 ;;^UTILITY(U,$J,358.3,8998,1,3,0)
+560 ;;=3^Kaposi's Sarcoma,Unspec
+561 ;;^UTILITY(U,$J,358.3,8998,1,4,0)
+562 ;;=4^C46.9
+563 ;;^UTILITY(U,$J,358.3,8998,2)
+564 ;;=^5001108
+565 ;;^UTILITY(U,$J,358.3,8999,0)
+566 ;;=C22.0^^45^431^104
+567 ;;^UTILITY(U,$J,358.3,8999,1,0)
+568 ;;=^358.31IA^4^2
+569 ;;^UTILITY(U,$J,358.3,8999,1,3,0)
+570 ;;=3^Liver Cell Carcinoma
+571 ;;^UTILITY(U,$J,358.3,8999,1,4,0)
+572 ;;=4^C22.0
+573 ;;^UTILITY(U,$J,358.3,8999,2)
+574 ;;=^5000933
+575 ;;^UTILITY(U,$J,358.3,9000,0)
+576 ;;=D05.02^^45^431^105
+577 ;;^UTILITY(U,$J,358.3,9000,1,0)
+578 ;;=^358.31IA^4^2
+579 ;;^UTILITY(U,$J,358.3,9000,1,3,0)
+580 ;;=3^Lobular Carcinoma in Situ,Left Breast
+581 ;;^UTILITY(U,$J,358.3,9000,1,4,0)
+582 ;;=4^D05.02
+583 ;;^UTILITY(U,$J,358.3,9000,2)
+584 ;;=^5001928
+585 ;;^UTILITY(U,$J,358.3,9001,0)
+586 ;;=D05.01^^45^431^106
+587 ;;^UTILITY(U,$J,358.3,9001,1,0)
+588 ;;=^358.31IA^4^2
+589 ;;^UTILITY(U,$J,358.3,9001,1,3,0)
+590 ;;=3^Lobular Carcinoma in Situ,Right Breast
+591 ;;^UTILITY(U,$J,358.3,9001,1,4,0)
+592 ;;=4^D05.01
+593 ;;^UTILITY(U,$J,358.3,9001,2)
+594 ;;=^5001927
+595 ;;^UTILITY(U,$J,358.3,9002,0)
+596 ;;=D05.00^^45^431^107
+597 ;;^UTILITY(U,$J,358.3,9002,1,0)
+598 ;;=^358.31IA^4^2
+599 ;;^UTILITY(U,$J,358.3,9002,1,3,0)
+600 ;;=3^Lobular Carcinoma in Situ,Unspec Breast
+601 ;;^UTILITY(U,$J,358.3,9002,1,4,0)
+602 ;;=4^D05.00
+603 ;;^UTILITY(U,$J,358.3,9002,2)
+604 ;;=^5001926
+605 ;;^UTILITY(U,$J,358.3,9003,0)
+606 ;;=R59.0^^45^431^66
+607 ;;^UTILITY(U,$J,358.3,9003,1,0)
+608 ;;=^358.31IA^4^2
+609 ;;^UTILITY(U,$J,358.3,9003,1,3,0)
+610 ;;=3^Enlarged Lymph Nodes,Localized
+611 ;;^UTILITY(U,$J,358.3,9003,1,4,0)
+612 ;;=4^R59.0
+613 ;;^UTILITY(U,$J,358.3,9003,2)
+614 ;;=^5019529
+615 ;;^UTILITY(U,$J,358.3,9004,0)
+616 ;;=C83.59^^45^431^108
+617 ;;^UTILITY(U,$J,358.3,9004,1,0)
+618 ;;=^358.31IA^4^2
+619 ;;^UTILITY(U,$J,358.3,9004,1,3,0)
+620 ;;=3^Lymphoblastic Lymphoma,Extranodal/Solid Organ Sites
+621 ;;^UTILITY(U,$J,358.3,9004,1,4,0)
+622 ;;=4^C83.59
+623 ;;^UTILITY(U,$J,358.3,9004,2)
+624 ;;=^5001590
+625 ;;^UTILITY(U,$J,358.3,9005,0)
+626 ;;=C83.50^^45^431^109
+627 ;;^UTILITY(U,$J,358.3,9005,1,0)
+628 ;;=^358.31IA^4^2
+629 ;;^UTILITY(U,$J,358.3,9005,1,3,0)
+630 ;;=3^Lymphoblastic Lymphoma,Unspec Site
+631 ;;^UTILITY(U,$J,358.3,9005,1,4,0)
+632 ;;=4^C83.50
+633 ;;^UTILITY(U,$J,358.3,9005,2)
+634 ;;=^5001581
+635 ;;^UTILITY(U,$J,358.3,9006,0)
+636 ;;=C43.9^^45^431^112
+637 ;;^UTILITY(U,$J,358.3,9006,1,0)
+638 ;;=^358.31IA^4^2
+639 ;;^UTILITY(U,$J,358.3,9006,1,3,0)
+640 ;;=3^Malig Melanoma of Skin,Unspec Site
+641 ;;^UTILITY(U,$J,358.3,9006,1,4,0)
+642 ;;=4^C43.9
+643 ;;^UTILITY(U,$J,358.3,9006,2)
+644 ;;=^5001015
+645 ;;^UTILITY(U,$J,358.3,9007,0)
+646 ;;=C31.9^^45^431^113
+647 ;;^UTILITY(U,$J,358.3,9007,1,0)
+648 ;;=^358.31IA^4^2
+649 ;;^UTILITY(U,$J,358.3,9007,1,3,0)
+650 ;;=3^Malig Neop Accessory Sinus,Unspec
+651 ;;^UTILITY(U,$J,358.3,9007,1,4,0)
+652 ;;=4^C31.9
+653 ;;^UTILITY(U,$J,358.3,9007,2)
+654 ;;=^5000953
+655 ;;^UTILITY(U,$J,358.3,9008,0)
+656 ;;=C24.1^^45^431^115
+657 ;;^UTILITY(U,$J,358.3,9008,1,0)
+658 ;;=^358.31IA^4^2
+659 ;;^UTILITY(U,$J,358.3,9008,1,3,0)
+660 ;;=3^Malig Neop Ampulla of Vater
+661 ;;^UTILITY(U,$J,358.3,9008,1,4,0)
+662 ;;=4^C24.1
+663 ;;^UTILITY(U,$J,358.3,9008,2)
+664 ;;=^267100
+665 ;;^UTILITY(U,$J,358.3,9009,0)
+666 ;;=C21.0^^45^431^116
+667 ;;^UTILITY(U,$J,358.3,9009,1,0)
+668 ;;=^358.31IA^4^2
+669 ;;^UTILITY(U,$J,358.3,9009,1,3,0)
+670 ;;=3^Malig Neop Anus,Unspec
+671 ;;^UTILITY(U,$J,358.3,9009,1,4,0)
+672 ;;=4^C21.0
+673 ;;^UTILITY(U,$J,358.3,9009,2)
+674 ;;=^5000930
+675 ;;^UTILITY(U,$J,358.3,9010,0)
+676 ;;=C67.9^^45^431^119
+677 ;;^UTILITY(U,$J,358.3,9010,1,0)
+678 ;;=^358.31IA^4^2
+679 ;;^UTILITY(U,$J,358.3,9010,1,3,0)
+680 ;;=3^Malig Neop Bladder,Unspec
+681 ;;^UTILITY(U,$J,358.3,9010,1,4,0)
+682 ;;=4^C67.9
+683 ;;^UTILITY(U,$J,358.3,9010,2)
+684 ;;=^5001263
+685 ;;^UTILITY(U,$J,358.3,9011,0)
+686 ;;=C71.9^^45^431^123
